Alnylam and Inceptive Partner in $2B Deal to Advance AI-Driven siRNA Drug Design
Alnylam Pharmaceuticals has announced a multi-year collaboration with Inceptive, an AI company focused on nucleic acid design, in a deal that could exceed $2 billion in value. Under the agreement, Alnylam will gain access to Inceptive's proprietary AI tools to accelerate the discovery and optimization of siRNA (small